StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Medicines Co. (MDCO), Alnylam Pharmaceuticals (ALNY) Announce Initiation of Phase III Clinical Trials of Inclisiran
November 6, 2017 7:16 AM
The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of the Phase III clinical ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'
November 8, 2017 11:54 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel
November 8, 2017 10:07 AM
The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
November 6, 2017 7:00 AM